{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:41:52Z","timestamp":1791981712627,"version":"4.4.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12022-025-09871-2","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T05:34:11Z","timestamp":1753248851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Reappraisal of Neuroendocrine Tumor Classification of the Prostate Gland: Translating Molecular Insights into Clinical Practice"],"prefix":"10.1007","volume":"36","author":[{"given":"Anandi","family":"Lobo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"9871_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12022-016-9421-z","volume":"27","author":"DS Priemer","year":"2016","unstructured":"Priemer DS, Montironi R, Wang L, Williamson SR, Lopez-Beltran A, Cheng L. Neuroendocrine tumors of the prostate: Emerging insights from molecular data and updates to the 2016 World Health Organization Classification. Endocr Pathol 2016; 27: 123-135.","journal-title":"Endocr Pathol"},{"key":"9871_CR2","doi-asserted-by":"crossref","unstructured":"Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Cheng LMorphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. Cells. 2020;9(5): 1073.","DOI":"10.3390\/cells9051073"},{"issue":"6","key":"9871_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1177\/10668969221116629","volume":"31","author":"SK Mohanty","year":"2023","unstructured":"Mohanty SK, Lobo A, Williamson SR, et al. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumours of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists. Int J Surg Pathol. 2023;31(6):993-1005.","journal-title":"Int J Surg Pathol."},{"issue":"2","key":"9871_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030593","volume":"9","author":"L Puca","year":"2019","unstructured":"Puca L, Vlachostergios PJ, Beltran H. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. Cold Spring Harb Perspect Med. 2019;9(2):a030593.","journal-title":"Cold Spring Harb Perspect Med."},{"key":"9871_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/14737140.2016.1226137","volume":"16","author":"MF Monn","year":"2016","unstructured":"Monn MF, Cheng L. Emerging trends in the evaluation and management of small cell prostate cancer: A clinical and molecular perspective. Expert Rev Anticancer Ther 2016; 16:1029-1037.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"9871_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","volume":"38","author":"JI Epstein","year":"2014","unstructured":"Epstein JI, Amin MB, Beltran H, et al. Proposed Morphologic Classification of Prostate Cancer with Neuroendocrine Differentiation. Am J Surg Pathol. 2014;38(6):756-767.","journal-title":"Am J Surg Pathol."},{"key":"9871_CR7","first-page":"630","volume":"1846","author":"M Santoni","year":"2014","unstructured":"Santoni M, Conti A, Burattini L, Berardi R, Scarpelli M, Cheng L. Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. Biochim Biophys Acta 2014; 1846:630-637.","journal-title":"Biochim Biophys Acta"},{"key":"9871_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.humpath.2022.08.006","volume":"136","author":"SK Mohanty","year":"2023","unstructured":"Mohanty SK, Lobo A, Cheng L. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol. 2023;136:123-143.","journal-title":"Hum Pathol."},{"key":"9871_CR9","unstructured":"WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Urinary and Male Genital Tumours. 5th ed, Vol 8, Lyon (France): Internnational Agency for Rsearch on Cancer (IARC), 2022."},{"issue":"S2","key":"9871_CR10","doi-asserted-by":"publisher","first-page":"S282","DOI":"10.21037\/tcr.2016.07.36","volume":"5","author":"MF Monn","year":"2016","unstructured":"Monn MF, Montironi R, Lopez-Beltran A, Cheng L. Emerging Molecular Pathways and Targets in Neuroendocrine Prostate Cancer. Transl Cancer Res 5(S2): S282-S285, 2016.","journal-title":"Transl Cancer Res"},{"issue":"S1","key":"9871_CR11","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1038\/modpathol.2017.164","volume":"31","author":"SW Fine","year":"2018","unstructured":"Fine SW. Neuroendocrine tumors of the prostate. Mod Pathol. 2018;31(S1):S122-132.","journal-title":"Mod Pathol."},{"key":"9871_CR12","volume-title":"Urologic Surgical Pathology","author":"L Cheng","year":"2026","unstructured":"Cheng L, MacLennan GT, Bostwick DG. Urologic Surgical Pathology, 5th edition, Elsevier, Philadelphia, PA, 2026.","edition":"5"},{"issue":"2","key":"9871_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/PAP.0000000000000431","volume":"31","author":"A Gopalan","year":"2024","unstructured":"Gopalan A. Treatment-related Neuroendocrine Prostate Carcinoma-Diagnostic and Molecular Correlates. Adv Anat Pathol. 2024;31(2):70-79.","journal-title":"Adv Anat Pathol."},{"issue":"10","key":"9871_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang Y, Ci X et al. Molecular events in neuroendocrine prostate cancer development. Nat Rev Urol. 2021;18(10):581-596.","journal-title":"Nat Rev Urol."},{"issue":"23","key":"9871_CR15","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Hruszkewycz A, Scher HI, et al. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res. 2019;25(23):6916-6924.","journal-title":"Clin Cancer Res."},{"issue":"20","key":"9871_CR16","doi-asserted-by":"publisher","first-page":"8105","DOI":"10.1073\/pnas.1221216110","volume":"110","author":"JC Pignon","year":"2013","unstructured":"Pignon JC, Grisanzio C, Geng Y, et al. p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc Natl Acad Sci USA. 2013;110(20):8105-8110.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"9871_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/00000478-200606000-00005","volume":"30","author":"JL Yao","year":"2006","unstructured":"Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 2006;30(6):705-712.","journal-title":"Am J Surg Pathol."},{"key":"9871_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.anndiagpath.2019.06.009","volume":"42","author":"AN Shehabeldin","year":"2019","unstructured":"Shehabeldin AN, Ro JY. Neuroendocrine tumors of genitourinary tract: Recent advances. Ann Diagn Pathol. 2019;42:48-58.","journal-title":"Ann Diagn Pathol."},{"issue":"7","key":"9871_CR19","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1365-2559.2010.03564.x","volume":"56","author":"VJ Scheble","year":"2010","unstructured":"Scheble VJ, Braun M, Wilbertz T, et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology. 2010;56(7):937-943.","journal-title":"Histopathology."},{"issue":"9","key":"9871_CR20","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mc.22162","volume":"54","author":"L Wang","year":"2015","unstructured":"Wang L, Williamson SR, Zhang S, et al. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. Mol Carcinog. 2015;54(9):900-907.","journal-title":"Mol Carcinog."},{"issue":"9","key":"9871_CR21","first-page":"3550","volume":"61","author":"MJ Linja","year":"2001","unstructured":"Linja MJ, Savinainen KJ, Saram\u00e4ki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001;61(9):3550-3555.","journal-title":"Cancer Res."},{"issue":"1","key":"9871_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/PAP.0000000000000245","volume":"27","author":"FA Faisal","year":"2020","unstructured":"Faisal FA, Lotan TL. The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy. Adv Anat Pathol. 2020 ;27(1):11-19.","journal-title":"Adv Anat Pathol."},{"key":"9871_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.humpath.2022.07.002","volume":"127","author":"E Abdulfatah","year":"2022","unstructured":"Abdulfatah E, Fine SW, Lotan TL, et al. De novo neuroendocrine features in prostate cancer. Hum Pathol. 2022;127:112-122.","journal-title":"Hum Pathol."},{"issue":"7051","key":"9871_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nature03918","volume":"436","author":"Z Chen","year":"2005","unstructured":"Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of PTEN-deficient tumorigenesis. Nature. 2005;436(7051):725-730.","journal-title":"Nature."},{"issue":"6320","key":"9871_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78-83.","journal-title":"Science."},{"key":"9871_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang M, Benelli WR, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 and RB1 deficient prostate cancer. Science. 2017;355:84\u201388.","journal-title":"Science."},{"issue":"4","key":"9871_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/iju.13526","volume":"25","author":"S Akamatsu","year":"2018","unstructured":"Akamatsu S, Inoue T, Ogawa O, et al. Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Int J Urol. 2018;25(4):345-351.","journal-title":"Int J Urol."},{"key":"9871_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487\u2013495.","journal-title":"Cancer Discov."},{"issue":"1","key":"9871_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Oromendia C, Danila DC, et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019;25(1):43-51.","journal-title":"Clin Cancer Res."},{"issue":"10","key":"9871_CR30","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.humpath.2014.06.008","volume":"45","author":"K Park","year":"2014","unstructured":"Park K, Chen Z, MacDonald TY, et al. Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Hum Pathol. 2014; 45(10):2136\u20132143.","journal-title":"Hum Pathol."},{"issue":"5","key":"9871_CR31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/pros.24664","volume":"84","author":"I de Kouchkovsky","year":"2024","unstructured":"de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. Diagnosis and management of neuroendocrine prostate cancer. Prostate. 2024;84(5):426-440.","journal-title":"Prostate."},{"issue":"1","key":"9871_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2353\/ajpath.2008.070602","volume":"172","author":"T Chiaverotti","year":"2008","unstructured":"Chiaverotti T, Couto SS, Donjacour A, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol. 2008;172(1):236-246.","journal-title":"Am J Pathol."},{"issue":"5","key":"9871_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289-297.","journal-title":"Nat Rev Cancer."},{"issue":"21","key":"9871_CR34","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-24-1388","volume":"84","author":"KE Rodarte","year":"2024","unstructured":"Rodarte KE, Nir Heyman S, Guo L et al. Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1. Cancer Res. 2024;84(21):3522-3537.","journal-title":"Cancer Res."},{"issue":"1","key":"9871_CR35","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1038\/s41467-022-29963-5","volume":"13","author":"S Nouruzi","year":"2022","unstructured":"Nouruzi S, Ganguli D, Tabrizian N et al. ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nat Commun. 2022;13(1):2282.","journal-title":"Nat Commun."},{"issue":"11","key":"9871_CR36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/oncolo\/oyac161","volume":"27","author":"J Yao","year":"2022","unstructured":"Yao J, Bergsland E, Aggarwal R, et al. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022;27(11):940-951.","journal-title":"Oncologist."},{"issue":"2","key":"9871_CR37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1158\/2767-9764.CRC-24-0501","volume":"5","author":"JR Lozada","year":"2025","unstructured":"Lozada JR, Elliott A, Evans MG, et al. Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting. Cancer Res Commun. 2025;5(2):318-326.","journal-title":"Cancer Res Commun."},{"key":"9871_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aav0891","volume":"11","author":"L Puca","year":"2019","unstructured":"Puca L, Gayvert K, Sailer V, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11:1\u201324.","journal-title":"Sci Transl Med."},{"key":"9871_CR39","doi-asserted-by":"crossref","unstructured":"Aggarwal RR, Aparicio A, Heidenreich A, et al.\u00a0Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).\u00a0J Clin Oncol. 2021;39:TPS5100-TPS5100.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5100"},{"issue":"8","key":"9871_CR40","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","volume":"52","author":"SG Zhao","year":"2020","unstructured":"Zhao SG, Chen WS, Li H, et al. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020;52(8):778-789.","journal-title":"Nat Genet."},{"issue":"4","key":"9871_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne E, Beltran H, Benelli M, et al. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 2016;30(4):563-577.","journal-title":"Cancer Cell."},{"key":"9871_CR42","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1038\/s12276-020-00542-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Tramontano A, Pezone A, et al. LSD1: More than demethylation of histone lysine residues. Exp Mol Med. 2020;52:1936\u20131947.","journal-title":"Exp Mol Med."},{"key":"9871_CR43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.neo.2020.04.002","volume":"22","author":"DJ Coleman","year":"2020","unstructured":"Coleman DJ, Sampson DA, Sehrawat A, et al. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRm4. Neoplasia. 2020;22:253\u2013262.","journal-title":"Neoplasia."},{"key":"9871_CR44","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1038\/s41467-020-19328-1","volume":"11","author":"J Cyrta","year":"2020","unstructured":"Cyrta J, Augspach A, De Filippo MR, et al. Role of specialized composition of SWI\/SNF complexes in prostate cancer lineage plasticity. Nat Commun. 2020;11:5549.","journal-title":"Nat Commun."},{"key":"9871_CR45","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/1097-0142(19850201)55:3<608::AID-CNCR2820550322>3.0.CO;2-S","volume":"55","author":"UA Almagro","year":"1985","unstructured":"Almagro UA. Argyrophilic prostatic carcinoma: case report with literature review on prostatic carcinoid and \u201ccarcinoid-like\u201d prostatic carcinoma. Cancer 1985;55: 608\u2013614.","journal-title":"Cancer"},{"key":"9871_CR46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/ajcp\/76.1.94","volume":"76","author":"MA Ansari","year":"1981","unstructured":"Ansari MA, Pintozzi RL, Choi YS, et al. Diagnosis of carcinoid-like metastatic prostatic carcinoma by an immunoperoxidase method. Am J Clin Pathol 1981;76: 94\u201398.","journal-title":"Am J Clin Pathol"},{"key":"9871_CR47","doi-asserted-by":"crossref","unstructured":"Alhamar M, Sethi S, Reuter VE, et al. Primary Well-Differentiated Neuroendocrine Tumor\/Carcinoid of the Prostate: Case Report and Review of Literature. Int J Surg Pathol. 2024:10668969241228297.","DOI":"10.1177\/10668969241228297"},{"key":"9871_CR48","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/1097-0142(19840915)54:6<1043::AID-CNCR2820540619>3.0.CO;2-U","volume":"54","author":"VS Ghali","year":"1984","unstructured":"Ghali VS, Garcia RL. Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome: immunohistochemical study and review of the literature. Cancer 1984;54:1043\u20131048.","journal-title":"Cancer"},{"key":"9871_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/106689690401200214","volume":"12","author":"JE Ghannoum","year":"2004","unstructured":"Ghannoum JE, DeLellis RA, Shin SJ. Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report. Int J Surg Pathol 2004;12:167\u2013170.","journal-title":"Int J Surg Pathol"},{"key":"9871_CR50","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1016\/S0022-5347(05)65024-0","volume":"167","author":"JA Tash","year":"2002","unstructured":"Tash JA, Reuter VE, Russo P. Metastatic carcinoid tumor of the prostate. J Urol 2002;167:2526\u20132527.","journal-title":"J Urol"},{"issue":"5","key":"9871_CR51","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.eururo.2009.01.019","volume":"56","author":"JPF Molenaar","year":"2009","unstructured":"Molenaar JPF, Baten A, Blokx WAM, et al. Development of carcinoid tumor in hormonally treated adenocarcinoma of the prostate. Eur Urol 2009;56(5):874\u2013877.","journal-title":"Eur Urol"},{"issue":"3","key":"9871_CR52","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s11255-009-9660-8","volume":"42","author":"S Giordano","year":"2010","unstructured":"Giordano S, Tolonen T, Tolonen T, et al. A pure primary low grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. Int Urol Nephrol 2010;42(3):683\u2013687.","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"9871_CR53","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.5858\/2004-128-e166-LNCCTO","volume":"128","author":"A Reyes","year":"2004","unstructured":"Reyes A, Moran CA. Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostateArch Pathol Lab Med 2004;128(12):e166\u2013168.","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"9871_CR54","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/BF03347481","volume":"27","author":"B Goulet-Salmon","year":"2004","unstructured":"Goulet-Salmon B, Berthe E, Franc S, et al. Prostatic neuroendocrine tumor in multiple endocrine neoplasia Type 2B. J Endocrinol Invest. 2004; 27(6):570\u2013573.","journal-title":"J Endocrinol Invest."},{"issue":"3 Pt 2","key":"9871_CR55","first-page":"1080","volume":"153","author":"T Whelan","year":"1995","unstructured":"Whelan T, Gatfield CT, Robertson S, et al. Primary carcinoid of the prostate in conjunction with multiple endocrine neoplasia IIb in a child. J Urol. 1995; 153(3 Pt 2):1080-1082.","journal-title":"J Urol."},{"issue":"6","key":"9871_CR56","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.21873\/anticanres.12589","volume":"38","author":"B P\u00f3sfai","year":"2018","unstructured":"P\u00f3sfai B, Kuthi L, Varga L, et al. The colorful palette of neuroendocrine neoplasms in the genitourinary tract. Anticancer Res 2018;38(6):3243\u20133254.","journal-title":"Anticancer Res"},{"issue":"11","key":"9871_CR57","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/j.1464-410X.2009.08451.x","volume":"103","author":"R Mazzucchelli","year":"2009","unstructured":"Mazzucchelli R, Morichetti D, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z. Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. BJU Int 2009;103(11):1464\u20131470.","journal-title":"BJU Int"},{"key":"9871_CR58","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Prostate Cancer (version 4.2024, May 17, 2024)."},{"issue":"36","key":"9871_CR59","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1200\/JCO.2011.41.5166","volume":"30","author":"H Beltran","year":"2012","unstructured":"Beltran H, Tagawa ST, Park K, et al. Challenges in recognizing treatment related neuroendocrine prostate cancer. J Clin Oncol. 2012;30(36):e386-389.","journal-title":"J Clin Oncol."},{"issue":"24","key":"9871_CR60","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. J Clin Oncol. 2018:36(24);2492-2503.","journal-title":"J Clin Oncol."},{"issue":"4","key":"9871_CR61","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cncr.24858","volume":"116","author":"SM Brennan","year":"2010","unstructured":"Brennan SM, Gregory DL, Stillie A, et al. Should extrapulmonary small cell cancers be managed like small cell lung cancer? Cancer. 2010;116(4):888-895.","journal-title":"Cancer."},{"issue":"3","key":"9871_CR62","doi-asserted-by":"publisher","first-page":"320","DOI":"10.5858\/arpa.2019-0434-RA","volume":"144","author":"J Hu","year":"2020","unstructured":"Hu J, Han B, Huang J. Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review. Arch Pathol Lab Med. 2020;144(3):320-325.","journal-title":"Arch Pathol Lab Med."},{"key":"9871_CR63","doi-asserted-by":"crossref","unstructured":"Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J SurgPathol. 2008; 32:65\u201371.","DOI":"10.1097\/PAS.0b013e318058a96b"},{"key":"9871_CR64","doi-asserted-by":"crossref","unstructured":"Huang J, Yao JL, di Sant\u2019Agnese PA, et al. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 2006;66(13):1399\u20131406.","DOI":"10.1002\/pros.20434"},{"key":"9871_CR65","doi-asserted-by":"crossref","unstructured":"Tetu B, Ro JY, Ayala AG, et al. Small cell carcinoma of the prostate. part I. A clinicopathologic study of 20 cases. Cancer. 1987;59(10):1803\u20131809.","DOI":"10.1002\/1097-0142(19870515)59:10<1803::AID-CNCR2820591019>3.0.CO;2-X"},{"key":"9871_CR66","doi-asserted-by":"crossref","unstructured":"Ro JY, Tetu B, Ayala AG, et al. Small cell carcinoma of the prostate. II. immunohistochemical and electron microscopic studies of 18 cases. Cancer. 1987;59(5):977\u2013982.","DOI":"10.1002\/1097-0142(19870301)59:5<977::AID-CNCR2820590521>3.0.CO;2-G"},{"issue":"6","key":"9871_CR67","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/modpathol.2011.7","volume":"24","author":"TL Lotan","year":"2011","unstructured":"Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 2011;24(6):820-828.","journal-title":"Mod Pathol."},{"issue":"1","key":"9871_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000224860","volume":"83","author":"E Sacco","year":"2009","unstructured":"Sacco E, Pinto F, Sasso F, et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int 2009;83(1):1\u201311.","journal-title":"Urol Int"},{"key":"9871_CR69","doi-asserted-by":"crossref","unstructured":"Rueda-Camino JA, Losada-Vila B, De Ancos-Aracil CL, et al. Small cell carcinoma of the prostate presenting with Cushing Syndrome. A narrative review of an uncommon condition. Ann Med 2016;48(4):293\u2013299.","DOI":"10.3109\/07853890.2016.1168936"},{"key":"9871_CR70","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/modpathol.3880044","volume":"13","author":"SN Agoff","year":"2000","unstructured":"Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13:238\u2013242.","journal-title":"Mod Pathol."},{"issue":"2","key":"9871_CR71","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5858\/2001-125-0228-IFTTFA","volume":"125","author":"W Cheuk","year":"2001","unstructured":"Cheuk W, Kwan MY, Suster S, et al. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med. 2001; 125(2):228\u2013231.","journal-title":"Arch Pathol Lab Med."},{"issue":"7","key":"9871_CR72","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.humpath.2005.04.007","volume":"36","author":"TD Jones","year":"2005","unstructured":"Jones TD, Kernek KM, Yang XJ, et al. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol. 2005; 36(7):718\u2013723.","journal-title":"Hum Pathol."},{"issue":"5","key":"9871_CR73","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1046\/j.1365-2559.2000.00890.x","volume":"36","author":"O Kaufmann","year":"2000","unstructured":"Kaufmann O and Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000; 36(5):415\u2013420.","journal-title":"Histopathology."},{"issue":"7","key":"9871_CR74","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/jcp.2010.077024","volume":"63","author":"AF Li","year":"2010","unstructured":"Li AF, Li AC, Hsu CY, et al. Small cell carcinomas in gastrointestinal tract: immunohistochemical and clinicopathological features. J Clin Pathol. 2010; 63(7):620\u2013625.","journal-title":"J Clin Pathol."},{"issue":"2","key":"9871_CR75","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1442-2050.2009.00981.x","volume":"23","author":"J Lu","year":"2010","unstructured":"Lu J, Xue LY, Lu N, et al. Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases. Dis Esophagus. 2010; 23(2):153\u2013159.","journal-title":"Dis Esophagus."},{"issue":"4","key":"9871_CR76","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/PAS.0b013e3181d1d457","volume":"34","author":"WG McCluggage","year":"2010","unstructured":"McCluggage WG, Kennedy K, Busam KJ. An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63. Am J Surg Pathol. 2010; 34(4):525\u2013532.","journal-title":"Am J Surg Pathol."},{"key":"9871_CR77","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2407-7-38","volume":"7","author":"JP Yun","year":"2007","unstructured":"Yun JP, Zhang MF, Hou JH, et al. Primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of 21 cases. BMC Cancer. 2007; 7:38.","journal-title":"BMC Cancer."},{"issue":"6","key":"9871_CR78","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/PAS.0000000000001444","volume":"44","author":"R Sakakibara","year":"2020","unstructured":"Sakakibara R, Kobayashi M, Takahashi N, et al. Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56. Am J Surg Pathol. 2020;44(6):757-764.","journal-title":"Am J Surg Pathol."},{"key":"9871_CR79","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/modpathol.2017.189","volume":"31","author":"A Yoshida","year":"2018","unstructured":"Yoshida A, Makise N, Wakai S, et al. INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma. Mod Pathol. 2018;31:744\u2013752.","journal-title":"Mod Pathol."},{"issue":"24","key":"9871_CR80","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-15-0744","volume":"21","author":"H Tsai","year":"2015","unstructured":"Tsai H, Morais CL, Alshalalfa M, et al. Cyclin D1 loss distinguishes prostatic small cell carcinoma from Most prostatic adenocarcinomas. Clin Cancer Res 2015;21(24):5619\u20135629.","journal-title":"Clin Cancer Res"},{"key":"9871_CR81","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/modpathol.2011.56","volume":"24","author":"SR Williamson","year":"2011","unstructured":"Williamson SR, Zhang S, Yao JL, et al. ERG::TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol. 2011;24:1120\u20131127.","journal-title":"Mod Pathol."},{"issue":"1","key":"9871_CR82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2010.05.026","volume":"42","author":"CC Guo","year":"2011","unstructured":"Guo CC, Dancer JY, Wang Y, et al. TMPRSS2::ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol. 2011; 42(1):11\u201317.","journal-title":"Hum Pathol."},{"key":"9871_CR83","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/pros.22836","volume":"74","author":"AM Udager","year":"2014","unstructured":"Udager AM, Shi Y, Tomlins SA, et al. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate. 2014;74:1199\u20131208.","journal-title":"Prostate."},{"key":"9871_CR84","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1126\/science.abn0478","volume":"377","author":"JM Chan","year":"2022","unstructured":"Chan JM, Zaidi S, Love JR, et al. Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling. Science. 2022;377:1180\u20131191.","journal-title":"Science."},{"key":"9871_CR85","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428\u201311436.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9871_CR86","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","volume":"20","author":"HL Tan","year":"2014","unstructured":"Tan HL, Sood A, Rahimi HA, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 2014;20:890\u2013903.","journal-title":"Clin Cancer Res"},{"key":"9871_CR87","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161: 1215\u20131228.","journal-title":"Cell."},{"key":"9871_CR88","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/pros.22598","volume":"73","author":"A Gupta","year":"2013","unstructured":"Gupta A, Yu X, Case T, et al. Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of FOXA2. Prostate. 2013;73:582\u2013589.","journal-title":"Prostate."},{"key":"9871_CR89","doi-asserted-by":"publisher","first-page":"14788","DOI":"10.1073\/pnas.1410419111","volume":"111","author":"A Augustyn","year":"2014","unstructured":"Augustyn A, Borromeo M, Wang T, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci USA. 2014;111:14788\u201314793.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"9871_CR90","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3390\/cancers16040805","volume":"16","author":"O Kouroukli","year":"2024","unstructured":"Kouroukli O, Bravou V, Giannitsas K, Tzelepi V. Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review. Cancers. 2024;16(4):805.","journal-title":"Cancers."},{"issue":"1","key":"9871_CR91","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO;2-#","volume":"29","author":"C Freeman","year":"1972","unstructured":"Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972; 29(1):252\u2013260.","journal-title":"Cancer."},{"issue":"2","key":"9871_CR92","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/0090-4295(88)90305-6","volume":"32","author":"DR Patel","year":"1988","unstructured":"Patel DR, Gomez GA, Henderson ES, et al. Primary prostatic involvement in non-Hodgkin lymphoma. Urology. 1988; 32(2):96\u201398.","journal-title":"Urology."},{"issue":"6","key":"9871_CR93","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/S0022-5347(01)67330-0","volume":"153","author":"A Sarris","year":"1995","unstructured":"Sarris A, Dimopoulos M, Pugh W, et al. Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. J Urol. 1995; 153(6): 1852\u20131854.","journal-title":"J Urol."},{"issue":"12","key":"9871_CR94","first-page":"1204","volume":"11","author":"MA Nandedkar","year":"1998","unstructured":"Nandedkar MA, Palazzo J, Abbondanzo SL, et al. CD45 (leukocyte common antigen) immunore activity in metastatic undifferentiated and neuroendocrine carcinoma: a potential diagnostic pitfall. Mod Pathol. 1998; 11(12):1204\u20131210.","journal-title":"Mod Pathol."},{"issue":"8","key":"9871_CR95","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/modpathol.2009.69","volume":"22","author":"B Han","year":"2009","unstructured":"Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009; 22(8):1083\u20131093.","journal-title":"Mod Pathol."},{"issue":"10","key":"9871_CR96","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.humpath.2013.05.005","volume":"44","author":"LA Schelling","year":"2013","unstructured":"Schelling LA, Williamson SR, Zhang S, et al. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol. 2013; 44(10):2227\u20132233.","journal-title":"Hum Pathol."},{"issue":"6","key":"9871_CR97","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/j.1464-410X.2011.10523.x","volume":"109","author":"S Deorah","year":"2012","unstructured":"Deorah S, Rao MB, Raman R, et al. Survival of patients with small cell carcinoma of the prostate during 1973\u20132003: a population-based study. BJU Int. 2012; 109(6):824-830.","journal-title":"BJU Int."},{"key":"9871_CR98","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","volume":"121","author":"V Conteduca","year":"2019","unstructured":"Conteduca V, Oromendia C, Eng KW, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7-18.","journal-title":"Eur J Cancer."},{"issue":"6","key":"9871_CR99","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/00000478-200606000-00003","volume":"30","author":"AJ Evans","year":"2006","unstructured":"Evans AJ, Humphrey PA, Belani J, et al. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006; 30(6):684\u2013693.","journal-title":"Am J Surg Pathol."},{"key":"9871_CR100","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/his.14707","volume":"81","author":"A Gopalan","year":"2022","unstructured":"Gopalan A, Al-Ahmadie H, Chen Y-B, et al. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series. Histopathology. 2022; 81:246\u2013254.","journal-title":"Histopathology."},{"issue":"1","key":"9871_CR101","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2559.2011.04039.x","volume":"60","author":"PA Humphrey","year":"2012","unstructured":"Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology. 2012; 60(1):59\u201374.","journal-title":"Histopathology."},{"issue":"12","key":"9871_CR102","first-page":"9061","volume":"7","author":"E Okoye","year":"2014","unstructured":"Okoye E, Choi EK, Divatia M, et al. De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature. Int J Clin Exp Pathol. 2014; 7(12):9061\u20139066.","journal-title":"Int J Clin Exp Pathol."},{"issue":"4","key":"9871_CR103","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1159\/000499883","volume":"103","author":"X Tu","year":"2019","unstructured":"Tu X, Chang T, Nie L, et al. Large cell neuroendocrine carcinoma of the prostate: a systematic review and pooled analysis. Urol Int. 2019;103(4):383-390.","journal-title":"Urol Int."},{"issue":"29","key":"9871_CR104","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/oncolo\/oyad344","volume":"4","author":"AV Serritella","year":"2024","unstructured":"Serritella AV, Beltran H, Lotan TL et al. Large Cell Neuroendocrine Prostate Cancer: Large Is Not Small. Oncologist. 2024;29:185-189.","journal-title":"Oncologist."},{"key":"9871_CR105","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0022-5347(17)37800-X","volume":"146","author":"ME Christopher","year":"1991","unstructured":"Christopher ME, Seftel AD, Sorenson K, et al. Small cell carcinoma of the genitourinary tract: an immunohistochemical, electron microscopic, and clinicopathological study. J Urol. 1991;146:382\u2013388.","journal-title":"J Urol."},{"key":"9871_CR106","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/0046-8177(94)90169-4","volume":"25","author":"H Bonkhoff","year":"1994","unstructured":"Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994;25: 42\u201346.","journal-title":"Hum Pathol"},{"key":"9871_CR107","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ijc.2910620304","volume":"62","author":"MA Noordzij","year":"1995","unstructured":"Noordzij MA, van der Kwast TH, van Steenbrugge GJ, et al. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study of patients treated by radical prostatectomy. Int J Cancer. 1995;62:252\u2013258.","journal-title":"Int J Cancer."},{"key":"9871_CR108","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/1097-0142(19840601)53:11<2478::AID-CNCR2820531119>3.0.CO;2-Q","volume":"53","author":"DS Schron","year":"1984","unstructured":"Schron DS, Gipson T, Mendelsohn G. The histogenesis of small cell carcinoma of the prostate: an immunohistochemical study. Cancer. 1984;53:2478\u20132480.","journal-title":"Cancer."},{"key":"9871_CR109","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/pros.20910","volume":"69","author":"DE Hansel","year":"2009","unstructured":"Hansel DE, Nakayama M, Luo J, et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate. 2009;69:603\u2013609.","journal-title":"Prostate."},{"key":"9871_CR110","unstructured":"Ikram A, Rehman A. Paraganglioma. 2024 Feb 29. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2024 Jan\u2013. PMID: 31751024."},{"key":"9871_CR111","doi-asserted-by":"crossref","unstructured":"Giannakodimos I, Ziogou A, Giannakodimos A, et al. Primary Paraganglioma of the Prostate: A Systematic Review of the Literature for A Rare Entity. Rev Recent Clin Trials. 2024 Feb 16.","DOI":"10.2174\/0115748871293735240209052044"},{"issue":"5\u20136","key":"9871_CR112","doi-asserted-by":"publisher","first-page":"E370","DOI":"10.5489\/cuaj.1221","volume":"7","author":"HH Wang","year":"2013","unstructured":"Wang HH, Chen YL, Kao HL, et al. Extra-adrenal paraganglioma of the prostate. Can Urol Assoc J. 2013;7(5-6):E370-2.","journal-title":"Can Urol Assoc J."},{"issue":"1","key":"9871_CR113","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clgc.2011.09.002","volume":"10","author":"Y Chen","year":"2012","unstructured":"Chen Y, Liu R, Zhang Z, et al. Paraganglioma arising from the prostate: a case report and review of the literature. Clin Genitourin Cancer. 2012;10(1):54-6.","journal-title":"Clin Genitourin Cancer."},{"issue":"1","key":"9871_CR114","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0022-5347(05)00252-1","volume":"175","author":"QK Li","year":"2006","unstructured":"Li QK, MacLennan GT. Paraganglioma of the prostate. J Urol. 2006;175(1):314.","journal-title":"J Urol."},{"key":"9871_CR115","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4137\/CCRep.S9742","volume":"5","author":"B Padilla-Fern\u00e1ndez","year":"2012","unstructured":"Padilla-Fern\u00e1ndez B, Ant\u00fanez-Plaza P, Lorenzo-G\u00f3mez MF, et al. Paraganglioma of prostatic origin. Clin Med Insights Case Rep. 2012;5:69-75.","journal-title":"Clin Med Insights Case Rep."},{"key":"9871_CR116","volume":"43","author":"F Hadj Kacem","year":"2022","unstructured":"Hadj Kacem F, Boujelben K, Feki W, et al. Pheochromocytoma of the prostate: An unusual location. Urol Case Rep. 2022;43:102108.","journal-title":"Urol Case Rep."},{"issue":"9","key":"9871_CR117","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/jcm7090280","volume":"7","author":"SL Asa","year":"2018","unstructured":"Asa SL, Ezzat S, Mete O. The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. J Clin Med. 2018;7(9):280.","journal-title":"J Clin Med."},{"issue":"10","key":"9871_CR118","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/modpathol.2013.76","volume":"26","author":"JS So","year":"2013","unstructured":"So JS, Epstein JI. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod Pathol. 2013;26(10):1365-1370.","journal-title":"Mod Pathol."},{"issue":"2","key":"9871_CR119","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s12022-020-09618-1","volume":"31","author":"N Kimura","year":"2020","unstructured":"Kimura N, Shiga K, Kaneko K, et al. The Diagnostic Dilemma of GATA3 Immunohistochemistry in Pheochromocytoma and Paraganglioma. Endocr Pathol. 2020;31(2):95-100.","journal-title":"Endocr Pathol."},{"issue":"6","key":"9871_CR120","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.humpath.2009.12.005","volume":"41","author":"AJ Gill","year":"2010","unstructured":"Gill AJ, Benn DE, Chou A, et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2010;41(6):805-814.","journal-title":"Hum Pathol."},{"issue":"8","key":"9871_CR121","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S1470-2045(09)70164-0","volume":"10","author":"FH van Nederveen","year":"2009","unstructured":"van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009;10(8):764-771.","journal-title":"Lancet Oncol."},{"key":"9871_CR122","doi-asserted-by":"crossref","unstructured":"Kimura N, Takayanagi R, Takizawa N, et al. Phaeochromocytoma Study Group in Japan. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. EndocrRelat Cancer. 2014;21(3):405\u2013414.","DOI":"10.1530\/ERC-13-0494"},{"issue":"11","key":"9871_CR123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187398","volume":"12","author":"JM Koh","year":"2017","unstructured":"Koh JM, Ahn SH, Kim H, et al. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One. 2017;12(11):e0187398.","journal-title":"PLoS One."},{"issue":"3","key":"9871_CR124","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.surg.2018.05.001","volume":"164","author":"YY Cho","year":"2018","unstructured":"Cho YY, Kwak MK, Lee SE, et al. A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score. Surgery. 2018;164(3):511-517.","journal-title":"Surgery."},{"issue":"6","key":"9871_CR125","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","volume":"474","author":"C Pierre","year":"2019","unstructured":"Pierre C, Agopiantz M, Brunaud L, et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas. Virchows Arch. 2019;474(6):721-734.","journal-title":"Virchows Arch."},{"issue":"2","key":"9871_CR126","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Leshchiner I, Walter V, et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. 2017;31(2):181-193.","journal-title":"Cancer Cell."},{"issue":"2","key":"9871_CR127","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","volume":"25","author":"S Job","year":"2019","unstructured":"Job S, Draskovic I, Burnichon N, et al. Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2019;25(2):760-770.","journal-title":"Clin Cancer Res."},{"key":"9871_CR128","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/2159-8290.CD-11-0259","volume":"1","author":"A Aparicio","year":"2011","unstructured":"Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov. 2011; 1: 466\u2013468.","journal-title":"Cancer Discov."},{"issue":"3","key":"9871_CR129","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298-305.","journal-title":"Nat Med."},{"issue":"2","key":"9871_CR130","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H. Clinical and Biological Features of Neuroendocrine Prostate Cancer. Curr Oncol Rep. 2021;23(2):15.","journal-title":"Curr Oncol Rep."},{"key":"9871_CR131","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.humpath.2022.06.004","volume":"127","author":"K Collins","year":"2022","unstructured":"Collins K, Cheng L. Morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review. Hum Pathol. 2022;127:56-66.","journal-title":"Hum Pathol."},{"issue":"6410","key":"9871_CR132","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aat5749","volume":"362","author":"JW Park","year":"2018","unstructured":"Park JW, Lee JK, Sheu KM, et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 2018;362(6410):91-95.","journal-title":"Science"},{"key":"9871_CR133","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.molcel.2020.10.033","volume":"80","author":"MA Rubin","year":"2020","unstructured":"Rubin MA, Bristow RG, Thienger PD, et al. Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. Mol Cell. 2020;80:562-577.","journal-title":"Mol Cell."},{"issue":"30","key":"9871_CR134","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","volume":"32","author":"HT Wang","year":"2014","unstructured":"Wang HT, Yao YH, Li BG, et al. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol. 2014;32(30):3383\u20133390.","journal-title":"J Clin Oncol."},{"key":"9871_CR135","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.humpath.2014.08.004","volume":"45","author":"JS So","year":"2014","unstructured":"So JS, Gordetsky J, Epstein JI. Variant of prostatic adenocarcinoma with Paneth cell\u2013like neuroendocrine differentiation readily misdiagnosed as Gleason pattern 5. Hum Pathol 2014;45:2388- 2393.","journal-title":"Hum Pathol"},{"issue":"12","key":"9871_CR136","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.3390\/cancers12123792","volume":"12","author":"N Spetsieris","year":"2020","unstructured":"Spetsieris N, Boukovala M, Patsakis G, et al. Neuroendocrine and Aggressive-Variant Prostate Cancer. Cancers (Basel). 2020;12(12):3792.","journal-title":"Cancers (Basel)."},{"key":"9871_CR137","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1200\/JCO.2002.12.065","volume":"20","author":"CN Papandreou","year":"2002","unstructured":"Papandreou C.N, Daliani D.D, Thall P.F, et al. Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate. J. Clin. Oncol. 2002; 20:3072\u20133080.","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"9871_CR138","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/path.5137","volume":"246","author":"EC Chedgy","year":"2018","unstructured":"Chedgy EC, Vandekerkhove G, Herberts C, et al. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. J Pathol. 2018;246(2):244-253.","journal-title":"J Pathol."},{"key":"9871_CR139","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pros.24497","volume":"83","author":"LS Graham","year":"2023","unstructured":"Graham LS, Haffner MC, Sayar E, et al. Clinical, pathologic and molecular features of amphicrine prostate cancer. The prostate. 2023;83:641\u2013648.","journal-title":"The prostate."},{"key":"9871_CR140","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/his.13330","volume":"71","author":"S Prendeville","year":"2017","unstructured":"Prendeville S, Al-Bozom I, Comperat E, et al. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumors of primary prostatic origin? Histopathology. 2017;71:926\u2013933.","journal-title":"Histopathology."},{"key":"9871_CR141","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/path.3987","volume":"227","author":"C Wu","year":"2021","unstructured":"Wu C, Wyatt AW, Lapuk AV, et al. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol. 2021;227:53\u201361.","journal-title":"J Pathol."},{"key":"9871_CR142","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/10668969211035844","volume":"30","author":"LA Galea","year":"2022","unstructured":"Galea LA, Mow C, Fine SW, et al. Primary prostate carcinoma with de novo diffuse neuroendocrine differentiation. Int J Surg Pathol. 2022;30:232\u2013236.","journal-title":"Int J Surg Pathol."},{"issue":"2","key":"9871_CR143","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00428-012-1259-2","volume":"461","author":"SS Jeetle","year":"2012","unstructured":"Jeetle SS, Fisher G, Yang ZH, et al. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch. 2012;461(2):103-107.","journal-title":"Virchows Arch."},{"key":"9871_CR144","doi-asserted-by":"crossref","unstructured":"Lotan TL, Tomlins SA, Bismar T, et al. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. Am J Surg Pathol. 2020;44(7):e15-e29.","DOI":"10.1097\/PAS.0000000000001450"},{"issue":"8","key":"9871_CR145","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/cncr.22971","volume":"110","author":"PE Spiess","year":"2007","unstructured":"Spiess PE, Pettaway CA, Vakar-Lopez F, et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer. 2007;110(8):1729-1737.","journal-title":"Cancer."},{"issue":"3","key":"9871_CR146","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000020289","volume":"38","author":"A Sella","year":"2000","unstructured":"Sella A, Konichezky M, Flex D, et al. Low PSA metastatic androgen- independent prostate cancer. Eur Urol. 2000;38(3):250-254.","journal-title":"Eur Urol."},{"issue":"5","key":"9871_CR147","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11912-017-0593-6","volume":"19","author":"PJ Vlachostergios","year":"2017","unstructured":"Vlachostergios PJ, Puca L, Beltran H. Emerging Variants of Castration-Resistant Prostate Cancer. Curr Oncol Rep. 2017;19(5):32.","journal-title":"Curr Oncol Rep."},{"issue":"13","key":"9871_CR148","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","volume":"19","author":"AM Aparicio","year":"2013","unstructured":"Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate9-resistant prostate cancer. Clin Cancer Res. 2013;19(13):3621-30.","journal-title":"Clin Cancer Res."},{"issue":"23","key":"9871_CR149","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. The New England journal of medicine. 2018;379(23):2220\u20132229.","journal-title":"The New England journal of medicine."},{"issue":"7","key":"9871_CR150","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. The Lancet Oncology. 2016;17(7):883\u2013895.","journal-title":"The Lancet Oncology."},{"issue":"1","key":"9871_CR151","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","volume":"82","author":"EY Yu","year":"2022","unstructured":"Yu EY, Kolinsky MP, Berry WR et al. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b\/2 KEYNOTE-365 Cohort B Study. Eur Urol. 2022;82(1):22-30.","journal-title":"Eur Urol."},{"issue":"suppl 2","key":"9871_CR152","doi-asserted-by":"publisher","first-page":"A449","DOI":"10.1136\/jitc-2021-SITC2021.419","volume":"9","author":"G Kramer","year":"2021","unstructured":"Kramer G, Shore N, Joshua A, et al. 419 Pembrolizumab +lenvatinib in patients with adenocarcinoma metastatic castration\u2010resistant prostate cancer (mCRPC) or treatment\u2010emergent neuroendocrine mCRPC: phase 1b\/2 KEYNOTE\u2010365 cohorts E\/F. J ImmunoTher Can. 2021;9(suppl 2): A449. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.419","journal-title":"J ImmunoTher Can."},{"issue":"suppl 2","key":"9871_CR153","doi-asserted-by":"publisher","first-page":"A455","DOI":"10.1136\/jitc-2021-SITC2021.425","volume":"9","author":"N Shore","year":"2021","unstructured":"Shore N, Bono JD, Kramer G, et al. 425 Pembrolizumab + vibostolimab in patients with adenocarcinoma metastatic castration\u2010resistant prostate cancer (mCRPC) or treatment\u2010emergent neuroendocrine mCRPC: phase 1b\/2 KEYNOTE\u2010365 cohorts G\/H. J ImmunoTher Can. 2021;9(suppl 2): A455. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.425","journal-title":"J ImmunoTher Can."},{"issue":"suppl 2","key":"9871_CR154","doi-asserted-by":"publisher","first-page":"A448","DOI":"10.1136\/jitc-2021-SITC2021.418","volume":"9","author":"JD Bono","year":"2021","unstructured":"Bono JD, Shore N, Kramer G, et al. 418 Phase 1b\/2 KEYNOTE\u2010365 cohort I: platinum\u2010containing chemotherapy alone or in combination with pembrolizumab for treatment\u2010emergent neuroendocrine prostate carcinoma. J ImmunoTher Can. 2021;9(suppl 2): A448. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.418","journal-title":"J ImmunoTher Can."},{"issue":"1","key":"9871_CR155","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","volume":"9","author":"L Puca","year":"2018","unstructured":"Puca L, Bareja R, Prandi D, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018;9(1):2404.","journal-title":"Nat Commun."},{"key":"9871_CR156","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","volume":"26","author":"RR Aggarwal","year":"2020","unstructured":"Aggarwal RR, Schweizer MT, Nanus DM, et al. A phase 1B\/ 2A study of the pan-BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer. Clin Cancer Res. 2020;26: 5338\u20135347.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"9871_CR157","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/pros.21301","volume":"71","author":"A Aparicio","year":"2011","unstructured":"Aparicio A, Tzelepi V, Araujo JC, et al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient\u2019s tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011; 71(8):846\u2013856.","journal-title":"Prostate."},{"issue":"6","key":"9871_CR158","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1158\/1078-0432.CCR-15-0137","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Jendrisak A, Landers M, et al. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2016;22(6):1510-1519.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"9871_CR159","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41416-022-01881-9","volume":"127","author":"B Trujillo","year":"2022","unstructured":"Trujillo B, Wu A, Wetterskog D et al. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br J Cancer. 2022;127(8):1394-1402.","journal-title":"Br J Cancer."},{"key":"9871_CR160","doi-asserted-by":"crossref","unstructured":"Romanel A, Gasi Tandefelt D, Conteduca V et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015;7:312re10.","DOI":"10.1126\/scitranslmed.aac9511"},{"key":"9871_CR161","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/1078-0432.CCR-24-2061","volume":"31","author":"MC Haffner","year":"2025","unstructured":"Haffner MC, Morris MJ, Ding CC et al. Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies. Clin Cancer Res. 2025; 31:466-478.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"9871_CR162","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00428-021-03202-6","volume":"480","author":"A Kasajima","year":"2022","unstructured":"Kasajima A, Konukiewitz B, Schlitter AM, et al. An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features. Virchows Arch. 2022;480(2):359-368.","journal-title":"Virchows Arch."},{"issue":"32","key":"9871_CR163","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.18632\/oncotarget.27695","volume":"11","author":"A Chauhan","year":"2020","unstructured":"Chauhan A, El-Khouli R, Waits T, et al. Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients. Oncotarget. 2020;11(32):3061-3068.","journal-title":"Oncotarget."},{"issue":"3","key":"9871_CR164","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/PAS.0b013e318208f96a","volume":"35","author":"YB Chen","year":"2011","unstructured":"Chen YB, Epstein JI. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases. Am J Surg Pathol. 2011;35(3):442-446.","journal-title":"Am J Surg Pathol."},{"key":"9871_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102941","volume":"136","author":"G Belge Bilgin","year":"2025","unstructured":"Belge Bilgin G, Lucien-Matteoni F, Chaudhuri AA, et al. Current and future directions in theranostics for neuroendocrine prostate cancer. Cancer Treat Rev. 2025;136:102941.","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"9871_CR166","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/path.6063","volume":"260","author":"W Butler","year":"2023","unstructured":"Butler W, Xu L, Zhou Y, et al. Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer. J Pathol 2023;260(1):43\u201355.","journal-title":"J Pathol"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-025-09871-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:02:13Z","timestamp":1768248133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-025-09871-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":166,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9871"],"URL":"https:\/\/doi.org\/10.1007\/s12022-025-09871-2","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"4 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"28"}}